Table_2_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.xlsx by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

DataSheet_8_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.pdf by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

Table_1_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.xlsx by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

DataSheet_3_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.pdf by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

Table_3_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.xlsx by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

DataSheet_9_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.pdf by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

Table_6_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.xlsx by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

DataSheet_4_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.pdf by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

Table_5_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.xlsx by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

Table_4_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.xlsx by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

Analyses of Lateral Gene Transfer Events in Bacteroidetes Lineages Reveal Its Contribution to Niche Specialization by Jian Xu (31545)

“…Significant increases (enrichment) relative to each whole genome are shown by an upward-pointing arrowhead, and decreases (depletion) by a downward-pointing arrowhead, whereas the corresponding probability, determined by a binomial test, is denoted by asterisks: a single asterisk (*) indicates <i>p</i> < 0.05; double asterisks (**) indicate <i>p</i> < 0.01; and triple asterisks (***) indicate <i>p</i> < 0.001.…”

Effects of Meloxicam on the Welfare of Holstein Calves from 6 Weeks to 6 Months Old Undergoing Amputation Dehorning by Jiancheng Qi (17878619)

“…<p dir="ltr"><a href="" target="_blank">Amputation </a>dehorning (AD) is a common practice performed on calves, causing harmful effects such as pain, distress, anxiety, fear. …”

Nature of Decahydro-<i>closo</i>-decaborate Anion Reorientations in an Ordered Alkali-Metal Salt: Rb₂B₁₀H₁₀ by Mirjana Dimitrievska (1494430)

“…Below this temperature range, NMR (and QENS) both indicate a shift to significantly larger reorientational barriers, for example, 485(8) meV for the apical exchanges. …”

Nature of Decahydro-<i>closo</i>-decaborate Anion Reorientations in an Ordered Alkali-Metal Salt: Rb₂B₁₀H₁₀ by Mirjana Dimitrievska (1494430)

“…Below this temperature range, NMR (and QENS) both indicate a shift to significantly larger reorientational barriers, for example, 485(8) meV for the apical exchanges. …”

Nature of Decahydro-<i>closo</i>-decaborate Anion Reorientations in an Ordered Alkali-Metal Salt: Rb₂B₁₀H₁₀ by Mirjana Dimitrievska (1494430)

“…Below this temperature range, NMR (and QENS) both indicate a shift to significantly larger reorientational barriers, for example, 485(8) meV for the apical exchanges. …”

DataSheet1_Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer.docx by Wenbo Qi (8863361)

“…Anlotinib 12 mg was administered orally daily before breakfast for 2 weeks with a week of rest in every cycle of 21 days. A reduction in alpha-fetoprotein, carcinoembryonic antigen, CA125, CA199, and CA724 levels was observed up to the first cycle, which decreased within the normal limits up to the second cycle and continued until the eighteenth cycle. …”

Image1_Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer.TIF by Wenbo Qi (8863361)

“…Anlotinib 12 mg was administered orally daily before breakfast for 2 weeks with a week of rest in every cycle of 21 days. A reduction in alpha-fetoprotein, carcinoembryonic antigen, CA125, CA199, and CA724 levels was observed up to the first cycle, which decreased within the normal limits up to the second cycle and continued until the eighteenth cycle. …”

Knockdown of Rab2A improves diet-induced hepatic lipid accumulation. by Zi-Yue Chen (11986539)

“…<p><b>(A)</b> Marked decreased protein levels of PPARγ were found in Rab2A-knockdown liver samples. …”

The strategic persistence of users. by Lingfei Wu (453300)

“…These density curves are obtained by applying the Gaussian kernel density estimation [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0149151#pone.0149151.ref016" target="_blank">16</a>] to fit the empirical distributions of <i>C</i>_<i>i</i> (it should be noted that unlike a probability, a probability density function can take on values greater than one). …”

Fig 4 - by Adam Lampert (413952)

“…The ACT* is also higher when <i>α</i> is larger. The sub-panels demonstrate the shape of the optimal treatment profile, <i>A</i>^opt, and the population density, <i>n</i>^opt, as a function of the location, <i>x</i>. …”